DK0857211T3 - Stærk homolog promoter fra hamster - Google Patents

Stærk homolog promoter fra hamster

Info

Publication number
DK0857211T3
DK0857211T3 DK96937224T DK96937224T DK0857211T3 DK 0857211 T3 DK0857211 T3 DK 0857211T3 DK 96937224 T DK96937224 T DK 96937224T DK 96937224 T DK96937224 T DK 96937224T DK 0857211 T3 DK0857211 T3 DK 0857211T3
Authority
DK
Denmark
Prior art keywords
hamster
promoter
homologous promoter
strong homologous
gene
Prior art date
Application number
DK96937224T
Other languages
Danish (da)
English (en)
Inventor
Klaus Bergemann
Barbara Enenkel
Frank Gannon
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Application granted granted Critical
Publication of DK0857211T3 publication Critical patent/DK0857211T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DK96937224T 1995-10-24 1996-10-24 Stærk homolog promoter fra hamster DK0857211T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19539493A DE19539493A1 (de) 1995-10-24 1995-10-24 Starker homologer Promotor aus Hamster
PCT/EP1996/004631 WO1997015664A1 (de) 1995-10-24 1996-10-24 Starker homologer promotor aus hamster

Publications (1)

Publication Number Publication Date
DK0857211T3 true DK0857211T3 (da) 2007-03-26

Family

ID=7775593

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96937224T DK0857211T3 (da) 1995-10-24 1996-10-24 Stærk homolog promoter fra hamster

Country Status (11)

Country Link
US (1) US6063598A (https=)
EP (2) EP0857211B1 (https=)
JP (2) JP3966903B2 (https=)
AT (1) ATE355370T1 (https=)
CA (1) CA2234071C (https=)
DE (2) DE19539493A1 (https=)
DK (1) DK0857211T3 (https=)
ES (1) ES2281905T3 (https=)
MX (1) MX9802764A (https=)
PT (1) PT857211E (https=)
WO (1) WO1997015664A1 (https=)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998032869A1 (en) * 1997-01-29 1998-07-30 Neurosearch A/S Expression vectors and methods for in vivo expression of therapeutic polypeptides
JP2004516016A (ja) * 2000-09-18 2004-06-03 ジェンザイム・コーポレイション ハイブリッドユビキチンプロモーターを含む発現ベクター
EP1624067A3 (en) * 2000-09-18 2006-03-15 Genzyme Corporation Expression vectors containing hybrid ubiquitin promoters
PT1600510E (pt) * 2001-07-04 2007-06-25 Chromagenics Bv Sequências de adn com actividade anti-repressora.
US7344886B2 (en) * 2002-11-29 2008-03-18 Boehringer Ingelheim Pharma Gmbh & Co., Kg Neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
DE10256083A1 (de) 2002-11-29 2004-08-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Expressionsvektor, Verfahren zur Herstellung von heterologen Genprodukten und Selektionsverfahren für hochproduzierende rekombinante Zellen
US7384744B2 (en) 2002-11-29 2008-06-10 Boehringer Ingelheim Pharma Gmbh & Co., Kg Expression vector, methods for the production of heterologous gene products and for the selection of recombinant cells producing high levels of such products
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US8669109B2 (en) 2003-08-19 2014-03-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methods of producing proteins in Chinese hamster ovary (CHO) cells
US20050101017A1 (en) * 2003-11-10 2005-05-12 Wojtek Auerbach Method of improving gene targeting using a ubiquitin promoter
GB0509965D0 (en) * 2005-05-17 2005-06-22 Ml Lab Plc Improved expression elements
US9163257B2 (en) * 2005-06-20 2015-10-20 Cadila Healthcare Limited Expression vector and methods of producing high levels of proteins
EP1806365A1 (en) 2006-01-05 2007-07-11 Boehringer Ingelheim International GmbH Antibody molecules specific for fibroblast activation protein and immunoconjugates containing them
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
DK2807188T3 (da) 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2938726B1 (en) 2012-12-31 2017-09-27 Boehringer Ingelheim International GmbH Heterologous intron within a signal peptide
WO2014102101A1 (en) 2012-12-31 2014-07-03 Boehringer Ingelheim International Gmbh Novel intron sequences
US10501531B2 (en) 2013-03-13 2019-12-10 Prothena Biosciences Limited Tau immunotherapy
US9989540B2 (en) 2013-05-10 2018-06-05 The Regents Of The University Of California Diagnostic and monitoring system for Huntington's disease
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
WO2015004633A1 (en) 2013-07-12 2015-01-15 Neotope Biosciences Limited Antibodies that recognize islet-amyloid polypeptide (iapp)
US9850302B2 (en) 2013-07-12 2017-12-26 Prothena Biosciences Limited Antibodies that recognize IAPP
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
DK3089760T3 (da) 2013-12-31 2020-03-16 Proteonic Biotechnology Ip B V Konstrukt og sekvens til forbedret genekspression
JP2017514458A (ja) 2014-03-12 2017-06-08 プロセナ バイオサイエンシーズ リミテッド Ｌｇ４−５に対して特異的な抗−ラミニン４抗体
KR20160131082A (ko) 2014-03-12 2016-11-15 프로테나 바이오사이언시즈 리미티드 Lg1-3에 특이적인 항-라미닌4 항체
PT3116911T (pt) 2014-03-12 2019-09-04 Prothena Biosciences Ltd Anticorpos anti-mcam e métodos de utilização associados
TW201623331A (zh) 2014-03-12 2016-07-01 普羅帝納生物科學公司 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
EP3230309B1 (en) 2014-12-10 2023-03-29 OPKO Biologics Ltd. Methods of producing long acting ctp-modified growth hormone polypeptides
TWI786505B (zh) 2015-01-28 2022-12-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI769570B (zh) 2015-01-28 2022-07-01 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
TWI718121B (zh) 2015-01-28 2021-02-11 愛爾蘭商普羅佘納生物科技有限公司 抗甲狀腺素運送蛋白抗體
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
WO2017011292A1 (en) 2015-07-15 2017-01-19 Zymtronix, Llc Automated bionanocatalyst production
EP3350226A2 (en) 2015-09-16 2018-07-25 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017046774A2 (en) 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
WO2017149513A1 (en) 2016-03-03 2017-09-08 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2017153955A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
WO2017153953A1 (en) 2016-03-09 2017-09-14 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases
PT3452507T (pt) 2016-05-02 2022-12-20 Prothena Biosciences Ltd Imunoterapia anti-tau
MY198194A (en) 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
MX2018013386A (es) 2016-05-02 2019-02-28 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2017208210A1 (en) 2016-06-03 2017-12-07 Prothena Biosciences Limited Anti-mcam antibodies and associated methods of use
WO2018007922A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
JP7016470B2 (ja) 2016-07-02 2022-02-07 プロセナ バイオサイエンシーズ リミテッド 抗トランスサイレチン抗体
WO2018007924A2 (en) 2016-07-02 2018-01-11 Prothena Biosciences Limited Anti-transthyretin antibodies
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
CA3031802A1 (en) 2016-08-13 2018-02-22 Zymtronix Catalytic Systems, Inc. Magnetically immobilized biocidal enzymes and biocidal chemicals
JP2020505025A (ja) 2017-01-13 2020-02-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 免疫工学的な改変をした多能性細胞
KR102784294B1 (ko) 2017-05-02 2025-03-19 프로테나 바이오사이언시즈 리미티드 타우 인식 항체
WO2019064053A1 (en) 2017-09-28 2019-04-04 Prothena Biosciences Limited DOSAGE REGIMES FOR THE TREATMENT OF SYNUCLEINOPATHIES
AU2018345807B2 (en) 2017-10-06 2025-02-06 Novo Nordisk A/S Methods of detecting transthyretin
PE20211453A1 (es) 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
EP3846938B1 (en) 2018-09-05 2024-08-07 ZYMtronix Catalytic Systems, Inc. Immobilized enzymes and microsomes on magnetic scaffolds
CU24781B1 (es) 2018-11-08 2026-02-09 Prothena Biosciences Ltd Anticuerpos humanizados que reconocen tau
EA202190986A1 (ru) 2018-11-26 2021-12-14 Фоти Севен, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА К c-Kit
JP7630834B2 (ja) 2019-03-03 2025-02-18 プロセナ バイオサイエンシーズ リミテッド タウ認識抗体
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US12221622B2 (en) 2019-05-10 2025-02-11 The Regents Of The University Of California Modified pluripotent cells
CA3144621A1 (en) 2019-06-26 2020-12-30 The Regents Of The University Of California Sirpalpha-silenced natural killer (nk) cells
US20220267732A1 (en) 2019-08-01 2022-08-25 Sana Biotechnology, Inc. Dux4 expressing cells and uses thereof
JP7728747B2 (ja) 2019-08-23 2025-08-25 サナ バイオテクノロジー，インコーポレイテッド Ｃｄ２４発現細胞およびそれらの用途
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
WO2021146471A2 (en) 2020-01-15 2021-07-22 The Regents Of The University Of California Transplanted cell protection via inhibition of polymorphonuclear cells
KR20220142433A (ko) 2020-01-17 2022-10-21 사나 바이오테크놀로지, 인크. 유전자 발현 조절용 안전 스위치
KR20220158046A (ko) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. 신경계 장애 및 병태의 치료를 위한 면역저하성 신경 세포
BR112022026508A2 (pt) 2020-06-24 2023-03-07 Prothena Biosciences Ltd Anticorpos que reconhecem sortilina
WO2022036150A1 (en) 2020-08-13 2022-02-17 Sana Biotechnology, Inc. Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
JP2024501971A (ja) 2020-12-31 2024-01-17 サナ バイオテクノロジー，インコーポレイテッド Ｃａｒ－ｔ活性を調節するための方法及び組成物
BR112023024231A2 (pt) 2021-05-19 2024-01-30 Sana Biotechnology Inc Células t primárias rhd negativas hipoimunogênicas
US20240226164A1 (en) 2021-05-27 2024-07-11 Sana Biotechnology, Inc. Hypoimmunogenic cells comprising engineered hla-e or hla-g
KR20240046319A (ko) 2021-07-14 2024-04-08 사나 바이오테크놀로지, 인크. 저면역원성 세포에서의 y 염색체-연결 항원의 변경된 발현
JP2024535677A (ja) 2021-08-11 2024-10-02 サナ バイオテクノロジー，インコーポレイテッド 即時血液媒介性炎症反応を減少させるための同種細胞療法を目的とした遺伝子改変細胞
AU2022325232A1 (en) 2021-08-11 2024-02-08 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
US20240358761A1 (en) 2021-08-11 2024-10-31 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy
EP4384598A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
EP4479416A1 (en) 2022-02-17 2024-12-25 Sana Biotechnology, Inc. Engineered cd47 proteins and uses thereof
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
WO2024125597A1 (en) 2022-12-14 2024-06-20 Providence Therapeutics Holdings Inc. Compositions and methods for infectious diseases
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
AU2024264889A1 (en) 2023-05-03 2025-11-13 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
EP4716541A2 (en) 2023-05-22 2026-04-01 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
TW202530246A (zh) 2023-09-15 2025-08-01 愛爾蘭商歐賽爾普羅希那有限公司 細胞穿透劑及其用途
AR133834A1 (es) 2023-09-15 2025-11-05 Prothena Biosciences Ltd Agentes de penetración célular y sus usos
WO2025059486A1 (en) 2023-09-15 2025-03-20 Prothena Biosciences Limited Anti-tdp-43 antibodies and uses thereof
WO2025059491A2 (en) 2023-09-15 2025-03-20 Prothena Platform Technologies Limited Methods, compositions, and kits including cell-penetrating agents
WO2025166633A2 (en) 2024-02-07 2025-08-14 Westlake Genetech. Ltd. Split gene editing systems and uses thereof

Also Published As

Publication number Publication date
JPH11513572A (ja) 1999-11-24
MX9802764A (es) 1998-11-30
EP0857211A1 (de) 1998-08-12
US6063598A (en) 2000-05-16
PT857211E (pt) 2007-03-30
WO1997015664A1 (de) 1997-05-01
DE19539493A1 (de) 1997-04-30
DE59611420D1 (de) 2007-04-12
CA2234071A1 (en) 1997-05-01
ATE355370T1 (de) 2006-03-15
EP1803815A2 (de) 2007-07-04
CA2234071C (en) 2003-01-21
EP1803815A3 (de) 2007-08-29
EP0857211B1 (de) 2007-02-28
JP3966903B2 (ja) 2007-08-29
ES2281905T3 (es) 2007-10-01
JP2006320330A (ja) 2006-11-30

Similar Documents

Publication Publication Date Title
DK0857211T3 (da) Stærk homolog promoter fra hamster
DK0920498T3 (da) Hamster EF-1alfa transskriptionelt, regulatorisk DNA
ATE420192T1 (de) Verfahren zur verringerung der antigenität des adeno-assoziierten virus strukturproteins
DK0830376T3 (da) Fremgangsmåde til fremstilling af erythropoietin, som er fri for animalske proteiner
BR9712656A (pt) Promotor, uso do mesmo, cassete de expressão, vetor recombinante, uso do mesmo, microorganismo, uso do mesmo, planta transgênica, processo de produção da mesma, processo de isolamento de um promotor especìfico para folha, e, sequência de ácido nucléico.
DK1062364T3 (da) Kvalitativ differentiel screening
PL1824977T3 (pl) Promotorowy kwas nukleinowy pochodzący z rodzaju Corynebacterium, kaseta ekspresyjna zawierająca promotor i wektor, komórka gospodarza zawierająca wektor i sposób ekspresji genu z użyciem komórki
ATE179754T1 (de) Verfahren zur herstellung von thrombin
ZA954781B (en) Nucleic acid sequences and expression systems for heparinase II and heparinase III derived from Flavobacterium heparinum
ATE264913T1 (de) Protease-resistente analoge des thrombomodulin
FI962099A0 (fi) Aspergillus Niger-karboksipeptidaasia koodaava geeni
DE69732847D1 (de) Endothel-spezifischer expression unter einfluss von epcr kontrollelementen
TR199701394T1 (xx) Gen ekspresyonu i�in promot�rler
ATE416257T1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
FR2693463B1 (fr) Promoteur de levure et son utilisation.
HUP9701904A2 (hu) D-panolakton hidroláz és az azt kódoló gén
ATE342998T1 (de) Replikation -defektive baculoviren expressionssystem
EP0811696A3 (en) Method to obtain nucleotide sequence using randomly primed amplification
ATE308612T1 (de) Als impfstoff verwendbares attenuiertes influenzavirus
DE69930294D1 (de) Minimale promotoren und ihre verwendung
DE69104357D1 (de) Klonierungs- und/oder expressionsvektoren, verfahren zur ihrer herstellung und verwendung.
HUP9902298A2 (hu) Tirozin-hidroxiláz génből származó expressziós rendszer
DK0859854T3 (da) Retrovirale vektorer bærende aldrende celle-afledte inhibitorer 1 (SDI-1) eller antisense SDI-1 nukleotidsekvenser
ATE458043T1 (de) Mn-gen und -protein
AU7416100A (en) Dihydroorotase extracted from plants